Yüklüyor......
A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder
OBJECTIVE: To test the safety of ublituximab, a B cell depleting agent, as add-on therapy in the acute treatment of relapses of neuromyelitis optica spectrum disorder. METHODS: We conducted an open-label phase 1b safety and proof-of-concept trial in 5 subjects with aquaporin-4 (AQP4)-immunoglobulin...
Kaydedildi:
| Yayımlandı: | Medicine (Baltimore) |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Wolters Kluwer Health
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6636936/ https://ncbi.nlm.nih.gov/pubmed/31232925 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000015944 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|